Dr. Ken Carlson brings over 18 years of expertise in medical monitoring, drug development and drug safety. As medical monitor, his experience encompasses a wide range of indications to include early phase oncology studies consisting of small molecule and immune-oncology drugs, solid tumors and hematologic cancers; cardiology, specifically hypertension, congestive heart failure, and anti-arrhythmic drugs; neurology such as Alzheimer’s disease and psychiatric disorders.
Dr. Carlson was also involved with the development of therapies for infectious diseases, male and female sexual dysfunction, and diabetes. In pulmonology he served as medical monitor for two pivotal phase III, multinational studies in asthma and COPD. He previously worked with several CRO’s including INC Research and Premier Research. Most recently he has served as a consultant for several Biotech companies: Astellas Pharma, Aveo Oncology, Karyopharma, Prescient Therapeutics, Takeda Millenium Oncology and Kowa Research Institute.
He completed undergraduate studies at the State University of New York with a BA in Biology and Lipid Chemistry. His undergraduate thesis work in familial amyotrophic chorea was published in the Annals of Neurology. He then attended medical school at the Albert Einstein College of Medicine in New York City and trained in general medicine at Montefiore Medical Center in the Bronx, New York. He practiced emergency medicine in a busy New York hospital for almost seven years before becoming the supervising physician.